These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34688843)
1. Experimental challenges to modeling prostate cancer heterogeneity. Flores-Téllez TDNJ; Baena E Cancer Lett; 2022 Jan; 524():194-205. PubMed ID: 34688843 [TBL] [Abstract][Full Text] [Related]
2. Nanoways to overcome docetaxel resistance in prostate cancer. Ganju A; Yallapu MM; Khan S; Behrman SW; Chauhan SC; Jaggi M Drug Resist Updat; 2014 Apr; 17(1-2):13-23. PubMed ID: 24853766 [TBL] [Abstract][Full Text] [Related]
3. Genomic and phenotypic heterogeneity in prostate cancer. Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650 [TBL] [Abstract][Full Text] [Related]
4. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing. Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308 [TBL] [Abstract][Full Text] [Related]
5. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Marusyk A; Janiszewska M; Polyak K Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Wyatt AW; Mo F; Wang K; McConeghy B; Brahmbhatt S; Jong L; Mitchell DM; Johnston RL; Haegert A; Li E; Liew J; Yeung J; Shrestha R; Lapuk AV; McPherson A; Shukin R; Bell RH; Anderson S; Bishop J; Hurtado-Coll A; Xiao H; Chinnaiyan AM; Mehra R; Lin D; Wang Y; Fazli L; Gleave ME; Volik SV; Collins CC Genome Biol; 2014 Aug; 15(8):426. PubMed ID: 25155515 [TBL] [Abstract][Full Text] [Related]
7. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. Nickel GC; Barnholtz-Sloan J; Gould MP; McMahon S; Cohen A; Adams MD; Guda K; Cohen M; Sloan AE; LaFramboise T PLoS One; 2012; 7(4):e35262. PubMed ID: 22536362 [TBL] [Abstract][Full Text] [Related]
8. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Liu W Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494 [TBL] [Abstract][Full Text] [Related]
9. The Heterogeneity of Prostate Cancer: A Practical Approach. Tolkach Y; Kristiansen G Pathobiology; 2018; 85(1-2):108-116. PubMed ID: 29393241 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Chakraborty G; Gupta K; Kyprianou N Nat Commun; 2023 Feb; 14(1):567. PubMed ID: 36732329 [TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis? Roy-Burman P; Zheng J; Miller GJ Mol Med Today; 1997 Nov; 3(11):476-82. PubMed ID: 9430782 [TBL] [Abstract][Full Text] [Related]
12. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No. Punnen S; Parekh DJ J Urol; 2017 Aug; 198(2):266-267. PubMed ID: 28629663 [No Abstract] [Full Text] [Related]